Therapeutic directions for Parkinson's disease
Identifieur interne : 002900 ( Main/Corpus ); précédent : 002899; suivant : 002901Therapeutic directions for Parkinson's disease
Auteurs : Ira ShoulsonSource :
- Movement Disorders [ 0885-3185 ] ; 2010.
English descriptors
Abstract
The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society
Url:
DOI: 10.1002/mds.22790
Links to Exploration step
ISTEX:91FC1C8ECF0E643B2693982141F90538422E0031Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic directions for Parkinson's disease</title><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:91FC1C8ECF0E643B2693982141F90538422E0031</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22790</idno><idno type="url">https://api.istex.fr/document/91FC1C8ECF0E643B2693982141F90538422E0031/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002900</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Therapeutic directions for Parkinson's disease</title><author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010">2010</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S152">S152</biblScope><biblScope unit="page" to="S154">S154</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">91FC1C8ECF0E643B2693982141F90538422E0031</idno><idno type="DOI">10.1002/mds.22790</idno><idno type="ArticleID">MDS22790</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>biomarkers</term><term>experimental therapeutics</term><term>uric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ira Shoulson MD</name><affiliations><json:string>Department of Neurology, University of Rochester, Rochester, New York, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>experimental therapeutics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>uric acid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>biomarkers</value></json:item></subject><articleId><json:string>MDS22790</json:string></articleId><language><json:string>eng</json:string></language><abstract>The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society</abstract><qualityIndicators><score>3.456</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>4</keywordCount><abstractCharCount>890</abstractCharCount><pdfWordCount>1956</pdfWordCount><pdfCharCount>13754</pdfCharCount><pdfPageCount>3</pdfPageCount><abstractWordCount>125</abstractWordCount></qualityIndicators><title>Therapeutic directions for Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>25</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>3</total><last>S154</last><first>S152</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S1</issue><author><json:item><name>Fahn Stanley MD</name></json:item><json:item><name>Marder Karen MD</name></json:item><json:item><name>Côté Lucien MD</name></json:item><json:item><name>Reich Stephen G. MD</name></json:item></author><subject><json:item><value>Future Developments in Treatment of PD</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22790</json:string></doi><id>91FC1C8ECF0E643B2693982141F90538422E0031</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/91FC1C8ECF0E643B2693982141F90538422E0031/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/91FC1C8ECF0E643B2693982141F90538422E0031/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/91FC1C8ECF0E643B2693982141F90538422E0031/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Therapeutic directions for Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported</note><note type="content">*On the occasion of the Parkinson's Disease Foundation 50th Anniversary Educational Symposium, October 11–12, 2007, New York, NY.</note><note>Uric acid biomarker discovery and development - No. NIH/NINDS NS24778;</note><note>DATATOP sponsor - No. NIH/NINDS R01 NS048517; No. NS054978; No. NIH/NIEHS R01 ES010804;</note><note>Parkinson Study Group</note><note>Michael J Fox Foundation</note><note>PRECEPT sponsors: Cephalon, Inc.</note><note>PostCEPT sponsors: NINDS - No. PD‐DOC NS050095;</note><note>Department of Defense NTERP Program (Imaging, PROBE Biomarkers)</note><note>Cephalon, Inc.</note><note>Parkinson's Disease Foundation (FOUND)</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Therapeutic directions for Parkinson's disease</title><author><persName><forename type="first">Ira</forename><surname>Shoulson</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA</p></note><affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">S1</biblScope><biblScope unit="page" from="S152">S152</biblScope><biblScope unit="page" to="S154">S154</biblScope></imprint></monogr><idno type="istex">91FC1C8ECF0E643B2693982141F90538422E0031</idno><idno type="DOI">10.1002/mds.22790</idno><idno type="ArticleID">MDS22790</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>experimental therapeutics</term></item><item><term>uric acid</term></item><item><term>biomarkers</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Future Developments in Treatment of PD</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-12-11">Received</change><change when="2009-08-21">Registration</change><change when="2010">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/91FC1C8ECF0E643B2693982141F90538422E0031/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="5"><doi origin="wiley" registered="yes">10.1002/mds.v25.1s</doi><titleGroup><title type="specialIssueTitle">Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">S1</numbering></numberingGroup><creators><creator xml:id="sped1" creatorRole="sponsoringEditor"><personName><givenNames>Fahn</givenNames><familyName>Stanley</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped2" creatorRole="sponsoringEditor"><personName><givenNames>Marder</givenNames><familyName>Karen</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped3" creatorRole="sponsoringEditor"><personName><givenNames>Côté</givenNames><familyName>Lucien</familyName><degrees>MD</degrees></personName></creator><creator xml:id="sped4" creatorRole="sponsoringEditor"><personName><givenNames>Reich</givenNames><familyName>Stephen G.</familyName><degrees>MD</degrees></personName></creator></creators><coverDate startDate="2010">2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="28" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22790</doi><idGroup><id type="unit" value="MDS22790"></id></idGroup><countGroup><count type="pageTotal" number="3"></count></countGroup><titleGroup><title type="articleCategory">Future Developments in Treatment of PD</title><title type="tocHeading1">Future Developments in Treatment of PD</title></titleGroup><copyright ownership="thirdParty">Copyright © 2010 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-12-11"></event><event type="manuscriptAccepted" date="2009-08-21"></event><event type="firstOnline" date="2010-02-25"></event><event type="publishedOnlineFinalForm" date="2010-02-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4 mode:FullText" date="2010-12-14"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S152</numbering><numbering type="pageLast">S154</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22790.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="15"></count><count type="wordTotal" number="2169"></count></countGroup><titleGroup><title type="main" xml:lang="en">Therapeutic directions for Parkinson's disease<link href="#fn1"></link> <link href="#fn2"></link></title><title type="short" xml:lang="en">Therapeutic Directions for PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Ira</givenNames><familyName>Shoulson</familyName><degrees>MD</degrees></personName><contactDetails><email>ira.shoulson@ctcc.rochester.edu</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">experimental therapeutics</keyword><keyword xml:id="kwd3">uric acid</keyword><keyword xml:id="kwd4">biomarkers</keyword></keywordGroup><fundingInfo><fundingAgency>Uric acid biomarker discovery and development</fundingAgency><fundingNumber>NIH/NINDS NS24778</fundingNumber></fundingInfo><fundingInfo><fundingAgency>DATATOP sponsor</fundingAgency><fundingNumber>NIH/NINDS R01 NS048517</fundingNumber><fundingNumber>NS054978</fundingNumber><fundingNumber>NIH/NIEHS R01 ES010804</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Parkinson Study Group</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Michael J Fox Foundation</fundingAgency></fundingInfo><fundingInfo><fundingAgency>PRECEPT sponsors: Cephalon, Inc.</fundingAgency></fundingInfo><fundingInfo><fundingAgency>PostCEPT sponsors: NINDS</fundingAgency><fundingNumber>PD‐DOC NS050095</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Department of Defense NTERP Program (Imaging, PROBE Biomarkers)</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Cephalon, Inc.</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Parkinson's Disease Foundation (FOUND)</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential conflict of interest: None reported</p></note><note xml:id="fn2"><p>On the occasion of the Parkinson's Disease Foundation 50th Anniversary Educational Symposium, October 11–12, 2007, New York, NY.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Therapeutic directions for Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Therapeutic Directions for PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Therapeutic directions for Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Ira</namePart><namePart type="family">Shoulson</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University of Rochester, Rochester, New York, USA</affiliation><description>Correspondence: Department of Neurology, University of Rochester, 1351 Mt Hope Avenue, Rochester, NY 14620, USA</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010</dateIssued><dateCaptured encoding="w3cdtf">2008-12-11</dateCaptured><dateValid encoding="w3cdtf">2009-08-21</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">15</extent><extent unit="words">2169</extent></physicalDescription><abstract lang="en">The focus on disease‐modifying treatments and cures for Parkinson's disease (PD) has raised expectations for quantum leaps and overshadowed incremental gains that have been slowly achieved. Large multi‐center clinical trials such as DATATOP and PRECEPT keep on generating new knowledge that is relevant to clinical care as well as experimental therapeutics. The largely unforeseen relationship between circulating uric acid and the occurrence and progression of PD was developed and confirmed in these clinical trials. Systematic follow‐up of clinical trial cohorts after conclusion of the interventional phase provides added value that continues to inform about natural history, state and trait biomarkers, and genotype‐phenotype relationships. These efforts are enhanced by data mining, public reporting, and timely sharing of data and biological samples. © 2010 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported</note><note type="content">*On the occasion of the Parkinson's Disease Foundation 50th Anniversary Educational Symposium, October 11–12, 2007, New York, NY.</note><note type="funding">Uric acid biomarker discovery and development - No. NIH/NINDS NS24778; </note><note type="funding">DATATOP sponsor - No. NIH/NINDS R01 NS048517; No. NS054978; No. NIH/NIEHS R01 ES010804; </note><note type="funding">Parkinson Study Group</note><note type="funding">Michael J Fox Foundation</note><note type="funding">PRECEPT sponsors: Cephalon, Inc.</note><note type="funding">PostCEPT sponsors: NINDS - No. PD‐DOC NS050095; </note><note type="funding">Department of Defense NTERP Program (Imaging, PROBE Biomarkers)</note><note type="funding">Cephalon, Inc.</note><note type="funding">Parkinson's Disease Foundation (FOUND)</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>experimental therapeutics</topic><topic>uric acid</topic><topic>biomarkers</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><name type="personal"><namePart type="given">Fahn</namePart><namePart type="family">Stanley</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Marder</namePart><namePart type="family">Karen</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Côté</namePart><namePart type="family">Lucien</namePart><namePart type="termsOfAddress">MD</namePart></name><name type="personal"><namePart type="given">Reich</namePart><namePart type="family">Stephen G.</namePart><namePart type="termsOfAddress">MD</namePart></name><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Future Developments in Treatment of PD</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="title"><title>Frontiers of Science and Clinical Advances in Quality of Life in Parkinson's Disease</title></detail><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>S1</number></detail><extent unit="pages"><start>S152</start><end>S154</end><total>3</total></extent></part></relatedItem><identifier type="istex">91FC1C8ECF0E643B2693982141F90538422E0031</identifier><identifier type="DOI">10.1002/mds.22790</identifier><identifier type="ArticleID">MDS22790</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2010 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002900 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002900 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:91FC1C8ECF0E643B2693982141F90538422E0031
|texte= Therapeutic directions for Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |